Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Jul;56(528):511-7.

Randomised controlled trial of near-patient testing for glycated haemoglobin in people with type 2 diabetes mellitus

Kamlesh Khunti  1 , Margaret A Stone, Andrew C Burden, David Turner, Neil T Raymond, Mary Burden, Richard Baker
Affiliations
Randomized Controlled Trial

Randomised controlled trial of near-patient testing for glycated haemoglobin in people with type 2 diabetes mellitus

Kamlesh Khunti et al. Br J Gen Pract. 2006 Jul.

Abstract

Background: Tight glycaemic control in people with type 2 diabetes can lead to a reduction in microvascular and possibly macrovascular complications. The use of near-patient (rapid) testing offers a potential method to improve glycaemic control.

Aim: To assess the effect and costs of rapid testing for glycated haemoglobin (HbA1c) in people with type 2 diabetes.

Design of study: Pragmatic open randomised controlled trial.

Setting: Eight practices in Leicestershire, UK.

Method: Patients were randomised to receive instant results for HbA1c or to routine care. The principal outcome measure was the proportion of patients with an HbA1c <7% at 12 months. We also assessed costs for the two groups.

Results: Of the 681 patients recruited to the study 638 (94%) were included in the analysis. The mean age at baseline was 65.7 years (SD = 10.8 years) with a median (interquartile range) duration of diabetes of 4(1-8) years. The proportion of patients with HbA1c < 7% did not differ significantly between the intervention and control groups (37 versus 38%, odds ratio 0.95 [95% confidence interval = 0.69 to 1.31]) at 12 months follow up. The total cost for diabetes-related care was 390 UK pounds per patient for the control group and 370 UK pounds for the intervention group. This difference was not statistically significant.

Conclusion: Near-patient testing for HbA1c alone does not lead to outcome or cost benefits in managing people with type 2 diabetes in primary care. Further research is required into the use of rapid testing as part of an optimised patient management model including arrangements for patient review and testing.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow of participants through the trial.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Turner RC, Holman RR, Cull CA, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–853. - PubMed
    1. Shamoon H, Duffy H, Fleischer N, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. - PubMed
    1. Gilmer TP, O'Connor PJ, Manning WG, Rush WA. The cost to health plans of poor glycemic control. Diabetes Care. 1997;20:1847–1853. - PubMed
    1. Menzin JP, Langley-Hawthorne CML, Friedman MM, et al. Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care. 2001;24:51–55. - PubMed
    1. Wagner EH, Sandhu N, Newton KM, et al. Effect of improved glycemic control on health care costs and utilization. JAMA. 2001;285:182–189. - PubMed

Publication types